Kimberly A. Selzman, MD, MPH

• Assistant Professor of Medicine
• Director of Electrophysiology
• George E. Wahlen Department of Veterans Affairs Medical Center
• Salt Lake City, Utah

A unique study in elderly patients with stable angina was the Trial of Invasive vs erectile dysfunction at age 30 order malegra fxt with a mastercard. At 1 year erectile dysfunction the facts purchase malegra fxt 140mg online, the primary endpoint of quality of life was equally improved with both strategies erectile dysfunction after zoloft order generic malegra fxt online. The invasive approach was associated with an early hazard erectile dysfunction doctors in memphis tn order malegra fxt on line, but there was no difference with regards to reduction in symptoms erectile dysfunction medication australia generic 140 mg malegra fxt with mastercard, death how does the erectile dysfunction pump work buy malegra fxt no prescription, or nonfatal infarction at 1 year. At 2 years following randomization, revascularization was associated with a lower mortality and a reduction in the composite endpoint of death, myocardial infarction, and recurrent hospitalization [20]. A surprising finding was that cardiac death and myocardial infarction were significantly lower in the group randomized to balloon angioplasty. The studies to date have had significant crossover to revasculari zation in those originally randomized to medical therapy and hence have been trials of "initial treatment strategies" rather than specific treatments. Aggressive secondary prevention is essential regardless of the treatment strategy utilized. At 5 years, there was no difference in the primary endpoints of the rates of survival (88. In a network metaanalysis from 100 trials in 93,553 patients with 262,090 patient years of followup, new generation drug eluting stents (everolimus: rate ratio 0. The findings are especially notable because the randomized trials have generally limited the enrolment to patients with single vessel disease and have excluded high risk patients with left main disease or chronic total occlusion for whom revascularization can offer greater benefit. The data demon strated that there was similar relief of symptoms with both forms of revascularization. However, revascularization resulted in a lower incidence of inducible ischemia compared to medical therapy alone, and all three strategies resulted in the effective treatment of limiting angina [17]. Importantly, the need for repeat revascularization during followup was greater with percutaneous revascularization using balloon angioplasty in both trials. By design, the inclusion criteria for these trials had mandated that the coronary anatomy was suitable for both forms of revascularization, thereby excluding most patients with very complex coronary anatomy or chronic total occlusions. One notable finding that has influenced current practice is that cardiac mortality was significantly lower (19. It has been speculated that the conflicting results between the regis try and the trial may have been because the treatment assignment in the registry was at the discretion of the physicians who might have selected the most appropriate form of revascularization for each patient [37]. The rates of death and myocardial infarction at 12 months were similar in the two groups. It is important to be aware that this evidence, which has been used to craft current guidelines, is limited by the fact that the randomized trials were all conducted in the early years of bypass surgery, and are not representative of the contemporary surgical techniques such as the routine use of internal mammary grafts or minimally invasive and offpump surgery [54]. Furthermore, the general applicability of these trials is limited by the fact that they did not enrol many women or patients over 65 years old. While medical therapy is the cornerstone of treatment of stable angina, it is important to remem ber that there is no evidence that medical therapy alone improves prognosis in high risk patients, as defined in the clinical trials of medical treatment vs. Revascularization in asymptomatic patients should only be considered with the goal of improving prognosis. The guidelines for the treatment of asymptomatic patients are similar to those for symptomatic patients. However, the level of evidence for asympto matic patients is weaker as the clinical trials have mainly included symptomatic patients. However, ischemia is an important therapeutic target in contemporary practice over and above the treatment of symptoms. Conclusions recommendations for revascularization in stable angina Broadly speaking, revascularization is appropriate for patients with limiting symptoms despite optimal medical therapy, strongly posi tive stress tests, proximal multivessel disease, and those who prefer an interventional approach over medical therapy. European Guidelines on cardiovascular disease prevention in clinical practice (version 2012). A comparison of angioplasty with medical ther apy in the treatment of singlevessel coronary artery disease. Percutaneous transluminal coronary angio plasty versus medical therapy for stable angina pectoris: outcomes for patients with doublevessel versus singlevessel coronary artery disease in a Veterans Affairs Cooperative randomized trial. Aggressive lipidlowering therapy compared with angioplasty in stable coronary artery disease. Percutaneous transluminal coronary angioplasty versus medical treatment for nonacute coronary heart disease: meta analysis of randomised controlled trials. Percutaneous coronary intervention versus conserva tive therapy in nonacute coronary artery disease: a metaanalysis. Percutaneous coronary intervention versus optimal medical therapy for prevention of spontaneous myocardial infarc tion in subjects with stable ischemic heart disease. Percutaneous coronary intervention versus medical therapy in stable coronary artery disease: the unre solved conundrum. Coronary angioplasty versus left internal mammary artery grafting for isolated proximal left anterior descending artery stenosis. Comparison of coronary bypass surgery with angioplasty in patients with multi vessel disease. A randomized study of coronary angio plasty versus bypasssurgery in patients with symptomatic multivessel coronary disease. A metaanalysis of randomized con trolled trials comparing coronary artery bypass graft with percutaneous translumi nal coronary angioplasty: one to eightyear outcomes. Survival of patients with diabetes and multivessel coronary artery disease after surgical or percutaneous coronary revas cularization: results of a large regional prospective study. Comparison of coronaryartery bypass surgery and stenting for the treatment of multivessel disease. Threeyear outcome after coronary stent ing versus bypass surgery for the treatment of multivessel disease. Randomized, controlled trial of coronary artery bypass surgery versus percutaneous coronary intervention in patients with multi vessel coronary artery disease: sixyear followup from the Stent or Surgery trial (SoS). Percutaneous coronary interven tions for multivessel disease: a collaborative analysis of individual patient data from ten randomised trials. Eighteenyear followup in the Veterans Affairs Cooperative Study of Coronary Artery Bypass Surgery for stable angina. Twelveyear followup of survival in the randomized European Coronary Surgery Study. Effect of coronary artery bypass graft surgery on survival: overview of 10year results from randomised trials by the Coronary Artery Bypass Graft Surgery Trialists Collaboration. Indications for coronary artery bypass sur gery and percutaneous coronary intervention in chronic stable angina: review of the evidence and methodological considerations. High risk patients derive more benefit from more aggressive man agement strategies. Risk stratification is based on clinical, electro cardiographic, and laboratory findings (Box 12. It is often considered more applicable to everyday clinical practice compared with other scores, as it was derived from a multinational registry of unselected patients from several hospitals around the world (Europe, Asia, North America, South America, Australia, and New Zealand). In general, the higher the baseline patient risk, the higher the likelihood of improving outcomes with aggressive treatment strategies, including cardiac catheterization and revascularization. Patients with signs and symptoms of ongoing ischemia, such as refractory angina and hemodynamic or electrical instability, should undergo urgent/immediate angiography (within 2 hours). Patients treated with an ischemiaguided strategy are treated with medical therapy alone unless they develop refractory angina, have myocardial ischemia in noninvasive evaluation, or are Interventional Cardiology: Principles and Practice, Second Edition. A metaanalysis of eight trials including >10,000 patients revealed significant reduction in the risk of death, myocar dial infarction, or rehospitalization with an acute coronary syn drome with an invasive strategy (odds ratio 0. The benefit was observed in both men and high risk women, but not in low risk women, supporting a conservative approach for the latter group [5]. Delayed angiography allows for stabilization of the patient and potential decrease of the intracoronary thrombus burden through antithrombotic therapy. Some studies have suggested that delaying angiography for several days may be detrimental [7]. In patients at low risk without recurrent symptoms or signs of ongoing ischemia, a non invasive assessment of inducible ischemia should be performed before discharge, followed by angiography if the findings suggest high risk. Occasionally, identification of the culprit lesion can be chal lenging and could be facilitated by use of intravascular imaging with optical coherence tomography, which can identify plaque rupture and thrombus formation [15]. In some cases no plaque rupture can be found, suggesting plaque erosion, which can often be successfully managed with medical therapy alone without stenting [16]. Three oral P2Y12 receptor Inhibitors are currently used: clopidogrel, prasugrel, and ticagrelor (ticlopidine is seldom used currently because of potential for serious hematologic side effects). In contrast, prasugrel and ticagrelor are more potent platelet inhibitors with consistent metabolism [21,22]. Prasugrel was harmful in patients with prior transient ischemic attack or stroke and did not provide clinical benefit among patients 75 years old or with <60 kg body weight [21]. North American patients did not derive benefit from ticagrelor administration, likely because of coadministration of 100 mg/day aspirin [27]. The currently guideline recommended duration is 12 months unless there are contraindi cations or an excessive risk of bleeding [1,2]. Some studies have suggested that shorter duration of P2Y12 inhibitor administra tion could be equivalent or superior to longer duration [28]. In patients pretreated with P2Y12 inhibitors, outcomes have been favorable with use of bivalirudin alone vs. It has low cost; however, response to unfractionated heparin is variable, requiring measurement of its antithrombotic effect. Risk stratification is key for determining optimal treat ment strategies, with higher risk patients deriving more benefit from more aggressive strategies. Clinical outcomes can be improved by optimal selection of anticoagulation and antiplatelet treatments. Treatment of myocardial infarction in a coronary care unit: a two year experience with 250 patients. Immediate vs delayed intervention for acute coronary syndromes: a randomized clinical trial. Evaluation of prolonged antithrombotic pretreatment ("coolingoff " strategy) before intervention in patients with unstable coronary syndromes: a randomized controlled trial. Staging of multivessel percutane ous coronary interventions: an expert consensus statement from the Society for Cardiovascular Angiography and Interventions. Culpritonly or multivessel revasculari zation in patients with acute coronary syndromes: an American College of Cardiology National Cardiovascular Database Registry report. Outcomes after complete versus incomplete revascularization of patients with multivessel coronary artery disease: a meta analysis of 89,883 patients enrolled in randomized clinical trials and observa tional studies. Assessment of culprit lesion morphology in acute myocardial infarction: ability of optical coherence tomography compared with intravascular ultrasound and coronary angioscopy. Prasugrel versus clopidogrel for acute coronary syndromes without revascularization. Following extensive pathologic investigation, it is now quite clear that the underlying etiologic mechanism involves acute disruption of an atherosclerotic plaque generally previously moderate in severity. The resultant exposure of circulating blood to underlying plaque material results in platelet aggregation, thrombin generation, and thrombosis [1]. A large region of myocardium undoubtedly suffers necrosis if not immediately addressed. Soon after the appreciation of thrombus and aggregated platelets at the occlusion site, substantial advances in care were made with the rapid administration of fibrinolytics, antiplatelets, and antithrombins aimed at reestablishing vessel patency. Along with these reperfusion studies conducted in the late 1980s and throughout the 1990s, coronary angiography was employed to assess the efficacy of therapy and the following observations were made. However, others expressed caution, reporting high complication rates including major bleeding and recurrent infarction, particularly when performed shortly after thrombolytic therapy [13]. Even when patients with cardiogenic shock were excluded, mortality was still reduced from 7% to 5%, with benefits sustained at longer term followup. Nonetheless, the results were widely embraced as angiography and intervention was safer and more predictable than fibronolytic therapy. In the first few hours there is significant opportunity for myocardial salvage with demonstrable Interventional Cardiology: Principles and Practice, Second Edition. These benefits decline with time although outcomes with reperfusion remain better for 24 hours as long as there is evidence of ongoing ischemia. The infarctrelated vessel is also revascularized by stent implantation nowadays, almost eliminating the risk of recurrent ischemia and infarction [23]. The best results are seen when a door2reperfusion time of <90 minutes is achieved. Unfortunately, further reductions in overall mortality have not been realized despite reductions to well below 90 minutes in recent years. Changes in demographics and patient risk could account for some of this attrition [27,28]. Technical approach and enhancements the infarctrelated vessel is occluded in most patients at the time of initial angiography. In others, a high grade stenosis is present with varying degrees of flow beyond the occlusion [22]. Thrombus accounts for most of the obstruction present and it is often easily traversed with a standard guidewire, although figuring the course of the occluded vessel can be difficult without experience. The obstruction is also easily dilatable given the contents are thrombus and soft plaque. Repeated angioplasty or stent implantation can then be performed to achieve definitive revascularization. In a few patients, angioplasty and even stent implantation does not establish normal flow. This is typically because of severe myocardial damage, tissue edema, or embolization of thrombotic debris to the distal microvasculature.

Plasma cholesterolinduced lesion networks activated before regression of early erectile dysfunction brochure discount 140mg malegra fxt mastercard, mature erectile dysfunction products cheap malegra fxt 140mg on-line, and advanced atherosclerosis erectile dysfunction treatment nasal spray cheap 140 mg malegra fxt visa. Carotid plaque age is a feature of plaque stability inversely related to levels of plasma insulin erectile dysfunction at age 19 buy generic malegra fxt 140 mg online. Transcriptional profiling uncovers a network of cholesterolresponsive atherosclerosis target genes erectile dysfunction drugs mechanism of action order malegra fxt overnight. The dynamic nature of coronary artery lesion morphology assessed by serial virtual histology intravascular ultrasound tissue characterization erectile dysfunction in diabetes type 1 buy generic malegra fxt 140 mg line. Natural disasters and myocardial infarction: the six years after hurricane Katrina. Acute myocardial infarction and stress cardio myopathy following the Christchurch earthquakes. Validated contextdependent associations of coronary heart disease risk with genotype variation in the chromosome 9p21 region: the atherosclerosis risk in communities study. Integrated transcriptional profiling and linkage analysis for identification of genes underlying disease. Systematic identification of trans eqtls as putative drivers of known disease associations. Onset and extent of platelet inhibition by clopidogrel loading in patients undergoing elective coronary stenting: the plavix reduction of new thrombus occurrence (pronto) trial. Consensus and future directions on the definition of high ontreatment platelet reactivity to adenosine diphosphate. Clopidogrel pharmacokinetics and phar macodynamics vary widely despite exclusion or control of polymorphisms (cyp2c19, abcb1, pon1), noncompliance, diet, smoking, comedications (including proton pump inhibitors), and preexistent variability in platelet function. Mdr1 pharmacogenetics: frequency of the c3435t mutation in exon 26 is significantly influenced by ethnicity. Genetic variants in abcb1 and cyp2c19 and cardiovascular outcomes after treatment with clopidogrel and prasugrel in the tritontimi 38 trial: a pharmacogenetic analysis. Abcb1 c3435t polymorphism and risk of adverse clinical events in clopidogrel treated patients: a metaanalysis. Genetic variation of cyp2c19 affects both pharmacokinetic and pharmacodynamic responses to clopidogrel but not prasug rel in aspirintreated patients with coronary artery disease. High doses of clopidogrel to overcome genetic resistance: the randomized crossover clovis2 (clopidogrel and response variability investigation study 2). Cyp2c19 but not pon1 genetic variants influence clopidogrel pharmacokinetics, pharmacodynamics, and clinical efficacy in post myocardial infarction patients. Influence of the paraoxonase1 q192r genetic variant on clopidogrel responsiveness and recurrent cardiovascular events: a systematic review and metaanalysis. Pon1 q192r genotype influences clopidogrel respon siveness by relative platelet inhibition instead of ontreatment platelet reactivity. The functional g143e variant of carboxy lesterase 1 is associated with increased clopidogrel active metabolite levels and greater clopidogrel response. Role of the p2y12 gene polymorphism in platelet responsiveness to clopidogrel in healthy subjects. Adverse drug reactions as cause of admission to hospital: prospective analysis of 18 820 patients. Pharmacogenetics and cardiovascular disease: implica tions for personalized medicine. Effect of genetic variants, especially cyp2c9 and vkorc1, on the pharmacology of warfarin. Influence of cyp2c9 and vkorc1 on patient response to warfarin: a systematic review and meta analysis. Cardiovascular pharmacogenomics; state of current knowledge and implementation in practice. Lim domain binding 2: a key driver of transendothelial migration of leukocytes and atherosclerosis. ChApteR 49 Monitoring and Reversal of Anticoagulation and Antiplatelet Agents Gregory W. Thrombogenic poten tial exists in a newly placed stent until there is complete endo thelialization [1], after ~28 days for bare metal stent and longer for drugeluting stents because of delayed neointimal proliferation [2,3]. Anticoagulation and dual antiplatelet therapy with stent placement is a standard of treatment with Class I indication according to cur rent practice guidelines [4]. There is a significant tradeoff with higher risk of major and minor bleeding when using greater combinations and doses of anticoagulation and antiplatelet for protection against thrombogenic and embolic events [11]. Unfractionated heparin Anticoagulants Exposure of clotting factors to disrupted endothelium, catheters, and guidewires predisposes to thrombosis during catheterization. Ideal anticoagulation would effectively prevent thrombus formation, have low risk of bleeding, a safe monitoring profile, short duration of effect (halflife), and could be Thrombus propagation occurs when thrombin is produced on the surface of activated platelets, converting fibrinogen to fibrin. While anticoagulants have been shown to inactivate von Willebrand factor there may be differences between anticoagu lants in curbing its release. This can be important in patients with unstable angina when there may be an early rise of von Willebrand factor. This early release of von Willebrand factor is associated with worse outcomes [19,20]. Unfractionated heparin remains the most commonly used anticoagulant despite the availability of newer medications. Studies have confirmed that thrombin bound to fibrin is pro tected from inactivation by heparin [23]. Reversal Heparin has a relatively short halflife; however, it has a nonlinear response when used at therapeutic doses. Intravenous protamine sulfate can be used when immediate reversal of heparin is needed. Slow infusion of protamine can reduce the chances of bradycardia, hypotension (no faster than 20 mg/minute and no more than 50 mg in any 10minute period). Heparin has a unique pentasaccharide sequence allowing it to bind to antithrombin, causing a conformational change and inactivating factor Xa. This complex can only be formed by pentasaccharide chains consisting of 18 saccharide units. A meta analysis of the two studies showed persistence of lower endpoints through 43 days. However, there were a nonnegligible number of patients who crossed over to the other antithrombotic agent, confounding the interpretation of the results. There may also be less incidence of bleeding associated with sheath removal [53,55]. An optimal antifactor Xa level has not been clearly defined; however, a therapeutic range of 0. The standard antifactor Xa activity laboratory study is not a method that can be readily used at the time of a catheterization procedure. Monitoring is not indicated in all situations but may be warranted in certain populations that may be at higher risk of bleeding. Antifactor Xa activity levels increased to appropriate levels when administered based on body weight up to 144 kg for enoxaparin, 190 kg for dalteparin, and 165 kg for tinazaparin [37]. Fondaparinux does not directly inhibit thrombin because it is a short molecule and unable to form a bridging complex between antithrombin and thrombin. Fondaparinux is subcutaneously injected, reaches peak levels in 2 hours, and is excreted in urine with a halflife of 17 hours in a younger population and ~21 hours in the elderly. It is typically administered once daily without monitoring because of its long halflife, bioavailability, and predictable anticoagulant response. It is contraindicated in renal insufficiency (creatinine clearance less than 30 mL/min) [13,35,37]. This study showed no significant dose responses between different doses of fondaparinux (2. There were no significant differences in fondaparinux plasma con centrations between groups with primary endpoints. Similarly, nonsignificant differences in plasma concentrations were seen in groups with bleeding versus those without bleeding. Fondaparinux was superior to enoxaparin in respect to significant reductions in major bleeding at 9 days, deaths at 30 days, and deaths at 180 days [72]. There were no significant differences in bleeding complications between the two doses but there was a trend for lower incidences with the 2. The procedural success rate was high in all groups with a slightly better percentage in the higher dose fondaparinux group: 96. Direct thrombin inhibitors are able to directly inhibit both circulating thrombin and clotbound thrombin. They are also more predictable than heparins because they do not acti vate platelets (thus not neutralized by platelet factor 4 when plate lets are activated) and do not bind to plasma proteins [79]. Bivalirudin Bivalirudin is a synthetic analogue of hirudin that is slowly cleaved by thrombin and only transiently inhibits thrombin. It is renally excreted; however, no adjustments need to be made until creatinine clearance (CrCl) is less than 30. Argatroban Argatroban is a small, synthetically derived, direct thrombin inhibi tor that reversibly binds to the active site of thrombin. It is meta bolized through the liver and has a halflife of approximately 45 minutes [81]. There was a nonsignificant lower incidence of bleeding in the argatroban group [91]. Argatroban is given intravenously with bolus dose of 350 g/kg followed by initial infusion rate of 25 g/kg/minute. Reversal of direct thrombin inhibitors (bivalirudin, argatroban) There are no specific reversal agents available for direct thrombin inhibitors. In normal healthy subjects with normal kidney function, coagulation times will return to normal within 1 hour of discon tinuing the infusion. Ticlopidine, clopi dogrel, and prasugrel irreversibly inhibit P2Y12, whereas ticagrelor and cangrelor are reversible inhibitors of P2Y12. Monitoring Although not routinely utilized in the clinical setting, multiple methods of monitoring platelet function have been developed over time. The bleeding time was the initial and is still the only in vivo test of platelet function. Initially developed as a measure of bleeding diatheses and the influence of platelet count, but after decades of broad clinical use it was subsequently found not to be predictive of clinical bleeding in the setting of surgery or antiplatelet therapy [103]. Several pointofcare antiplatelet assays have been developed and studied in research settings; however, similar to bleeding time, there has been no clinical evidence that shows the clinical benefit of these monitoring methods. However, this test is labor intensive and technically demanding, Antiplatelets Platelets have a key role in arterial thrombotic events. Once normal endothelium is compromised, platelet adhesion, activation, and aggregation lead to thrombus formation. Platelet aggregation leads to for mation of a platelet plug which is further anchored by fibrin mesh developed from the coagulation cascade [14,95]. Steps of the cascade can be interrupted by different classes of antiplatelet agents in order to minimize the risk of arterial throm bosis. Thienopyridines (ticlopidine, clopidogrel, prasugrel) and other adenosine diphosphate Table 49. Rarely does the anti platelet effect of aspirin need to be reversed, with the exception of intracranial bleeding. However, if bleeding from aspirin needs to be reversed immediately, platelet concentrate can be administered, although banked platelets are also functionally diminished. This study showed that clopidogrel is a safe and effective alternative to aspirin [106]. Further aggregation suppression was not significant with doses higher than 600 mg. In contrast, clopidogrel is more slowly absorbed and only ~15% undergoes met abolic activation [35]. Ticagrelor is a novel, nonthienopyridine, reversible P2Y12 inhibitor that has a rapid onset of action within 30 minutes to peak platelet inhibition within 2 hours.

The most common routes by which antigen is introduced experimentally or as a vaccine into the body are into tissue by subcutaneous (s erectile dysfunction medications that cause discount malegra fxt 140 mg otc. Antigens injected subcutaneously generally elicit strong responses erectile dysfunction protocol guide discount malegra fxt master card, most probably because the antigen is taken up by resident dendritic cells in the skin and efficiently presented in local lymph nodes erectile dysfunction karachi purchase malegra fxt visa, and so this is the method most commonly used when the object of the experiment is to elicit specific antibodies or T cells against a given antigen erectile dysfunction liver order generic malegra fxt from india. Antigens injected or transfused directly into the bloodstream tend to induce immune unresponsiveness or tolerance unless they bind to host cells or are in the form of aggregates that are readily taken up by antigen-presenting cells impotent rage man buy malegra fxt 140mg visa. Antigen administration via the gastrointestinal tract is used mostly in the study of allergy erectile dysfunction treatment brisbane order cheapest malegra fxt and malegra fxt. It has distinctive effects, frequently eliciting a local antibody response in the intestinal lamina propria, while producing a systemic state of tolerance that manifests as a diminished response to the same antigen if subsequently administered in immunogenic form elsewhere in the body (see Chapter 12). In general, secondary and subsequent immune responses occur at lower antigen doses and achieve higher plateau values, which is a sign of immunological memory. Most proteins are poorly immunogenic or nonimmunogenic when administered by themselves. Strong adaptive immune responses to protein antigens almost always require that the antigen be injected in a mixture known as an adjuvant. An adjuvant is any substance that enhances the immunogenicity of substances mixed with it. First, adjuvants convert soluble protein antigens into particulate material, which is more readily ingested by phagocytic antigen-presenting cells such as macrophages and dendritic cells. The activated antigen-presenting cells upregulate abundant levels of co-stimulatory molecules that are important for activating T cells. Slightly higher doses seem to inhibit specific antibody production, an effect known as low-zone tolerance. Above these doses there is a steady increase in the response with antigen dose until an optimum response is reached; this response persists across a broad range of doses. Very high doses of antigen also inhibit immune responsiveness to a subsequent challenge, a phenomenon known as high-zone tolerance. Adjuvants are mixed with the antigen and usually render it particulate, which helps to retain the antigen in the body and promotes uptake by macrophages. Most adjuvants include bacteria or bacterial components that stimulate macrophages and dendritic cells, aiding in the induction of the immune response. Thus, the antigen-presenting cell can stimulate a response to the viral protein, much as a virus infecting these cells would stimulate an antiviral response. B cells contribute to adaptive immunity by secreting antibodies, and the response of B cells to an injected immunogen is usually measured by analyzing the specific antibody produced in a humoral immune response. This is most conveniently achieved by assaying the antibody that accumulates in the fluid phase of the blood, or plasma; such antibodies are known as circulating antibodies. Circulating antibody is usually measured by collecting blood, allowing it to clot, and then isolating the serum from the clotted blood. The amount and characteristics of the antibody in the resulting antiserum are then determined using the assays described below. Because assays for antibody were originally conducted using antisera from immune individuals, they are commonly referred to as serological assays, and the use of antibodies in such testing is often called serology. The most important characteristics of an antibody response are the specificity, amount, isotype or class, and affinity of the antibodies produced. The spec ificity determines the ability of the antibody to distinguish the immunogen Appendix I from other antigens. The amount of antibody can be determined in many different ways and is a function of the number of responding B cells, their rate of antibody synthesis, and the persistence of the antibody after production. The persistence of an antibody in the plasma and extracellular fluid bathing the tissues is determined mainly by its isotype or class (see Sections 5-12 and 10-14); each isotype has a different half-life in vivo. The isotypic composition of an antibody response also determines the biological functions these antibodies can perform and the sites in which antibody will be found. Finally, the strength of binding of the antibody to its antigen in terms of a single antigen-binding site binding to a monovalent antigen is termed its affinity; the total binding strength of a molecule with more than one binding site is called its avidity. Binding strength is important: the higher the affinity of the antibody for its antigen, the less antibody is required to eliminate the antigen, because antibodies with higher affinity will bind at lower antigen concentrations. All these parameters of the humoral immune response help to determine the capacity of that response to protect the host from infection. The specificity of antigen:antibody binding interactions can be exploited for the purification of a specific antigen from a complex mixture, or alternatively, for the purification of specific antibodies from antiserum containing a mixture of different antibodies. For purification of an antigen, antigen-specific antibodies are bound, often covalently, to small, chemically reactive beads, which are loaded into a column. The specific antigen binds; all the other components in the mixture can then be washed away. Antibodies bind stably under physiological conditions of salt concentration, temperature, and pH, but the binding is reversible because the bonds are noncovalent. Affinity chromatography can also be used to purify antibodies from complex antisera by using beads coated with specific antigen. The technique is known as affinity chromatography because it separates molecules on the basis of their affinity for one another. For both of these methods, one needs a pure preparation of a known antigen or antibody, or both, in order to standardize the assay. The unlabeled component, which in this case would be the solution containing an unknown amount of antigen, is attached to a solid support, such as the wells of a plastic multiwell plate, which will adsorb a certain amount of any protein. To purify a specific antigen from a complex mixture of molecules, a monoclonal antibody is attached to an insoluble matrix, such as chromatography beads, and the mixture of molecules is passed over the matrix. The specific antibody binds the antigen of interest; other molecules are washed away. Antibodies can be purified in the same way on beads coupled to antigen (not shown). The use of such a second layer amplifies the signal, because at least two molecules of the labeled anti-immunoglobulin antibody are able to bind to each unlabeled antibody. Rather than the antigen being directly attached to a plastic plate, antigen-specific antibodies are bound to the plate. These are able to bind antigen with high affinity, and thus concentrate it on the surface of the plate, even with antigens that are present in very low concentrations in the initial mixture. A separate labeled antibody that recognizes a different epitope from that recognized by the immobilized first antibody is then used to detect the bound antigen. Another variant of the antigen-capture assay, often referred to as a multiplex assay, has been developed to allow quantitation of multiple antigens in a single sample. This technique is often utilized to examine the levels of multiple cytokines in clinical serum samples, or in sera from experimental animals, cases in which it is not feasible to assess each cytokine of interest individually. For this type of assay, small microspheres are differentially labeled with fluorescent dyes that can be distinguished based on their distinct emission spectra. Microspheres labeled with a given fluorescent dye are conjugated to antibodies specific for one antigen, for instance, a single cytokine. The microspheres- up to 100 different microspheres with unique identifiers-are added to the sample to capture the antigen. Bound antigen is then detected using a second antibody that binds the antigen at a distinct site. This second antibody is conjugated to a different fluorescent dye, and the magnitude of its fluorescence is a measure of the quantity of bound antigen. The machine that performs this multiplex analysis, the Luminex analyzer, then measures the amount of fluorescence associated with each differentially labeled microsphere. First, at least one of the reagents must be available in a pure, detectable form in order to obtain quantitative information. Second, there must be a means of separating the bound fraction of the labeled reagent from the unbound, free fraction so that the percentage of specific binding can be determined. Normally, this separation is achieved by having the unlabeled partner trapped on a solid support. Labeled molecules that do not bind can then be washed away, leaving just the labeled partner that has bound. The separation of bound reagent from the free fraction is an essential step in every assay that uses antibodies. To detect antigen A, purified antibody specific for antigen A is linked chemically to an enzyme. The samples to be tested are coated onto the surface of plastic wells, to which they bind nonspecifically; residual sticky sites on the plastic are blocked by adding irrelevant proteins (not shown). The labeled antibody is then added to the wells under conditions that prevent nonspecific binding, so that only binding to antigen A causes the labeled antibody to be retained on the surface. Unbound labeled antibody is removed from all wells by washing, and bound antibody is detected by an enzyme-dependent color-change reaction. This assay allows arrays of wells known as microtiter plates to be read in fiberoptic multichannel spectrometers, greatly speeding the assay. A fixed amount of unlabeled antibody is attached to a set of wells, and a standard reference preparation of a labeled antigen is bound to it. Unlabeled standard or test samples are then added in various amounts and the displacement of labeled antigen is measured, generating characteristic inhibition curves. A standard curve is obtained by using known amounts of unlabeled antigen identical to that used as the labeled species, and comparison with this curve allows the amount of antigen in unknown samples to be calculated. The green line on the graph represents a sample lacking any substance that reacts with anti-A antibodies. A standard curve is first constructed by adding various amounts of a known, unlabeled standard preparation; the assay can then measure the amount of antigen in unknown samples by comparison with the standard. The competitive binding assay can also be used for measuring antibody in a sample of unknown composition by attaching the appropriate antigen to the plate and measuring the ability of the test sample to inhibit the binding of a labeled specific antibody. The direct measurement of antibody binding to antigen is used in most quantitative serological assays. However, some important assays are based on the ability of antibody binding to alter the physical state of the antigen to which the antibody binds. For instance, when the antigen is displayed on the surface of a large particle such as a bacterium, antibodies can cause the bacteria to clump, or agglutinate. The same principle applies to the reactions used in blood typing, only here the target antigens are on the surface of red blood cells and the clumping reaction caused by antibodies against them is called hemagglutina tion (from the Greek haima, blood). These blood-group antigens are arrayed in many copies on the surface of the red blood cell, causing the cells to agglutinate when cross-linked by antibodies. Because hemagglutination involves the cross-linking of blood cells by the simultaneous binding of antibody molecules to identical antigens on different cells, this reaction also demonstrates that each antibody molecule must have at least two identical antigen-binding sites. Coombs tests use anti-immunoglobulin antibodies to detect the antibodies that cause hemolytic disease of the newborn, or erythroblastosis fetalis. Anti-immunoglobulin antibodies were first developed by Robin Coombs, and the test for this disease is still called the Coombs test. Hemolytic disease of the newborn occurs when a mother makes IgG antibodies specific for the rhesus or Rh bloodgroup antigen expressed on the red blood cells of her fetus. Rh-negative mothers make these antibodies when they are exposed at delivery to Rh-positive fetal red blood cells bearing the paternally inherited Rh antigen. During subsequent pregnancies, these antibodies are transported across the placenta to the fetus. This normal process is generally beneficial, as it protects newborn infants against infection. However, IgG anti-Rh antibodies coat the fetal red blood cells, which are then destroyed by phagocytic cells in the liver, causing a hemolytic anemia in the fetus and newborn infant. Rh antigens are widely spaced on the red blood cell surface, and so the IgG anti-Rh antibodies do not bind in the correct conformation to fix complement and so do not cause lysis of red blood cells in vitro. Thus, detecting anti-Rh antibodies was difficult until anti-human immunoglobulin antibodies were developed. With these, maternal IgG antibodies bound to the fetal red blood cells can be detected after washing the cells to remove unbound immunoglobulin that is present in the fetal serum. Adding anti-human immunoglobulin antibodies against the washed fetal red blood cells agglutinates any cells to which maternal antibodies are bound. The indirect Coombs test allows Rh incompatibilities that might lead to hemolytic disease of the newborn to be detected, and this knowledge allows the disease to be prevented (see Section 15-10). The Coombs test is also commonly used to detect antibodies against drugs that bind to red blood cells and cause hemolytic anemia. The antibodies generated in a natural immune response or after immunization in the laboratory are a mixture of molecules of different specificities and affinities. Some of this heterogeneity results from the production of antibodies that bind to different epitopes on the immunizing antigen, but even antibodies directed at a single antigenic determinant such as a hapten can be markedly heterogeneous, as shown by isoelectric focusing. In this technique, proteins are separated on the basis of their isoelectric point, the pH at which their net charge is zero. By electrophoresing proteins in a pH gradient for long enough, each molecule migrates along the pH gradient until it reaches the pH at which it is neutral and is thus concentrated (focused) at that point. When antiserum containing anti-hapten antibodies is treated in this way and then transferred to a solid support such as nitrocellulose paper, the anti-hapten antibodies can be detected by their ability to bind labeled hapten. The binding of antibodies of various isoelectric points to the hapten shows that even antibodies that bind the same antigenic determinant can be heterogeneous. Antisera are valuable for many biological purposes but they have certain inherent disadvantages that relate to the heterogeneity of the antibodies they contain. First, each antiserum is different from all other antisera, even if raised in a genetically identical animal by using the identical preparation of antigen and the same immunization protocol. Second, antisera can be produced in only limited volumes, and thus it is impossible to use the identical serological reagent in a long or complex series of experiments or clinical tests. Finally, even antibodies purified by affinity chromatography (see Section A-3) can include minor populations of antibodies that give unexpected cross-reactions, which confound the analysis of experiments.

A fat saturation prepulse can be applied if necessary and the images are obtained from fast acquisi tions every other heartbeat and do not require a breath hold erectile dysfunction gene therapy order malegra fxt mastercard. They are useful for the evaluation of intraluminal abnormalities as in aortic dissec tion or for the localization of pulmonary veins [5] erectile dysfunction causes medications purchase on line malegra fxt. The human body is com posed of ~70% water and water is formed from two hydrogen atoms and one oxygen atom erectile dysfunction injection therapy video generic 140 mg malegra fxt otc. Cine imaging allows evaluation of ventricular wall motion impotence underwear buy 140mg malegra fxt with mastercard, wall thickening erectile dysfunction frequency cheap malegra fxt 140 mg with mastercard, measurement of chamber sizes smoking and erectile dysfunction causes order genuine malegra fxt line, and assessment of valvular morphology and function. It is also very useful for assessing the motion of the myocardium relative to the pericardium. T1 images are often used for contrastenhanced studies while T2 and T2* imaging have mostly been used in noncontrast approaches. T2* relaxation times are significantly altered by the myocardial iron content and their quantification provides an excellent marker for iron overload [2]. Pixelwise T1 and T2 maps whereby an estimate of T1/T2 is encoded in the intensity of each pixel allows for quantification of the parameter of interest. Perfusion imaging for the assessment of myocardial blood flow and ischemia is performed at rest and with a pharmacologic vasodi lator stress agent such as adenosine or regadenoson. Most fre quently, a trained observer qualitatively examines the myocardium for low signal or hypoperfusion relative to normally perfused seg ments. Velocityencoding phase shifts result from the sequential application of bipolar mag netic field gradients of opposite polarity. The first gradient pro duces a phase shift that is reversed by the second pulse such that stationary spins will have no net phase at the end of the sequence. However, flowing spins will acquire a net phase change dependent on velocity in the direction of the flowencoding gradients [18]. Aliasing results in artifactual reduc tion of measured flow while a Venc setting that is too high leads to increased noise or inaccuracy of flow or velocity measurement [5]. The magnitude data provide the map of protons within the slice, giving the conventional crosssectional image. The intensity of a pixel in a phase image reflects the velocity of the protons within that pixel. Evaluation of the intensity of a region of pixels provides quantitative data reflecting the flow of blood through a portion of the heart or artery [18]. Multiplanar review, which allows visualization of the vessel in crosssection and evalua tion of vessel walls, can also be performed. An oblique sagittal "candy cane" view which reduces the thickness of the imaging slab can be used to minimize breath hold time. Abdominal, pelvic, and lower extremity runoff studies are usually obtained in the coronal plane and are well accepted for com prehensive evaluation of the vasculature in patients likely to require revascularization [20,21]. This is further com pounded by the fact that coronary arteries are only stationary for brief periods of the cardiac cycle. The most successful techniques for imaging coronary arteries utilize navigator echobased cardiac gated techniques to minimize respiratory motion [23,24]. The sequence is time consuming and the distal coronary segments are not well visualized. Thus, the major utility of this technique is for assessing the origins and to a limited degree the course of the coronary arteries. A 20gauge intravenous catheter is placed in an arm vein for the administration of the contrast agent. A second intravenous line is placed in the contralateral arm if a pharmacologic stress agent is to be administered. The first step in the preparation of a patient is screening to ensure that there are no major contraindications such as implanted cere brovascular clips, cochlear implants, ocular metallic fragments, neural stimulators, or insulin pumps. In addition, the wires and generator can sometimes be associated with significant artifact and other imaging modalities have to be considered. Regional biventricular function can be assessed qualitatively and quantitatively by myocardial tagging. Nonischemic etiologies of heart failure either do not have detectable scars or have a nonsubendocardial distribution that is very distinct from ischemic subendocardial to transmural patterns. In dilated cardiomyopathy, a midmyocardial stripe of septal fibrosis is more typical and is of strong prognostic value [32]. In cardiac iron overload, quantification of T2* relaxation times have proven useful for estimating intramyocardial iron content [35]. Coronary anomalies are rare (~1% of the general population [37]) and usually benign. Congenital cor onary anomalies in which the anomalous segment courses between the aorta and pulmonary artery are a wellrecognized cause of myo cardial ischemia and sudden cardiac death, especially among young adults [38,39]. In comparison with the native coronary arteries, reverse saphenous vein and internal mam mary artery grafts are relatively easy to image because of their mini mal motion during the cardiac and respiratory cycles and the larger lumen of reverse saphenous vein grafts. The assessment of grafts has shown good correlation with quantita tive Xray angiography for both graft occlusion and stenosis. Fatty and or fibrous replacement of the myocardium may be found on histology but this is not considered to be specific for the disease. On a retrospective study of Sarcoidosis Up to 50% of patients with pulmonary sarcoidosis have cardiac involvement which is the leading cause of death in these patients. Myocardial involvement could be subendocardial to transmural and does not follow a coronary distribution. Amyloidosis Myocardial amyloid accumulation is often a consequence of sys temic amyloidosis with resultant increase in ventricular wall thick ness. Hemochromatosis Cardiac iron overload in diseases such as thalassemia and heredi tary hemochromatosis can lead to dilatation, hypertrophy, and dys function. Myocardial T2* quantification, which can be accurately determined, has been shown to be a more efficacious marker of cardiac iron involvement and guidance of chelation ther apy than serial liver biopsies [35,70]. It also provides superior tissue characterization including an estimate of inflammation [2,71]. Tagged cine can be used to demonstrate tethering or adhesion of the pericardial layers which impairs the normal sliding motion of the pericardium across the myocardium. This is particularly helpful in the subset of patients with organized pericardial effusions or pericardial adhesions and normal pericardial thickness [2]. The caval contributions of blood flow to each lung in patients with single ventricle physiology who have undergone Glenn and Fontan procedures can be deter mined [77]. These techniques are used in the following conditions: 1 Aneurysm: to elucidate etiology and identify associated aortic valve abnormalities for presurgical planning 2 Atherosclerosis and penetrating ulcer: to identify aortic pseudo aneurysms, noncommunicating dissection 3 Traumatic injury: to identify aortic wall hemorrhage and differ entiate between partial and circumferential tears 4 Dissection: to identify acute versus chronic states, delineate the extent and locate antry and exit flaps, measure flow in the true and false lumen, differentiate from intramural hematoma and assess associated aortic valve involvement 5 Aortitis: detection of wall inflammation and measurement of wall thickness in response to treatment. The pressure gradient is then calculated by plug ging the velocities into the Bernoulli equation. Aortic stents placed during intervention interfere with assessment of the coarctation postintervention but collateral flow estimation is unaffected. This is crucial in preprocedural assessment for percutaneous pulmonary valve implantation, as certain anatomic criteria are to be met for the safe anchoring of the valve [98,102,103]. Invasive receiver coil imaging of peripheral arterial atheromata has been reported [106,107]. Case Study A 59yearold man with a history of hypertension, hyperlipidemia, and cocaine abuse was admitted to a local hospital with a 3day history of substernal chest pain, dyspnea, and diaphoresis. One month after discharge, he presented in congestive heart failure with shortness of breath, a new murmur, and an enlarged cardiac silhouette on chest Xray. Six days postsurgery he had an episode of sustained monomorphic ventricular tachycardia. The electrophysiology team was consulted and an implantable cardiac defibrillator was placed. In this case, valuable information on the extent of ventricular damage was obtained for surgical planning. Myocardial function in infarcted and remote regions early after infarction in man: assessment by magnetic resonance tagging and strain analysis. Subclinical atherosclerosis and incipi ent regional myocardial dysfunction in asymptomatic individuals. Characterization of acute and chronic myocar dial infarcts by multidetector computed tomography comparison with contrast enhanced magnetic resonance. Regional heterogeneity of human myocardial infarcts demonstrated by contrastenhanced mri potential mechanisms. Cardiovascular Flow measurement with phasecontrast mr imaging: basic facts and implementation 1. Coronary artery imaging in grown up congenital heart disease complementary role of magnetic resonance and Xray coronary angiography. Modern pacemaker and implantable cardioverter/defibrillator systems can be magnetic resonance imaging safe: in vitro and in vivo assessment of safety and function at 1. Differentiation of heart failure related to dilated cardiomyopathy and coronary artery disease using gadolinium enhanced cardiovascular magnetic resonance. Myocardial scarring in asympto matic or mildly symptomatic patients with hypertrophic cardiomyopathy. Toward clinical risk assessment inhypertrophic cardiomyopathy withgadolinium cardio vascular magnetic resonance. Cardiovascular Magnetic resonance, fibro sis, and prognosis in dilated cardiomyopathy. Development of thalassaemic iron overload cardiomyopathy despite low liver iron levels and meticulous compliance to desferrioxamine. Identification of anomalous coronary arteries and their anatomic course by magnetic resonance coronary angiography. Major variations in anatomical origin of the coronary arteries: angiographic observations in 4,250 patients without associated congenital heart disease. Sudden death as a complication of anomalous left coronary origin from the anterior sinus of valsalva a notsominor congenital anomaly. Hemodynamically significant primary anoma lies of the coronary arteries: angiographic aspects. Magnetic resonance angiogra phy isequivalent to Xray coronary angiography for the evaluation of coronary arteries in kawasaki disease. Magnetic resonance angiogra phy, function and viability evaluation in patients with Kawasaki disease. Value of magnetic resonance imaging for the noninvasive detection of stenosis in coronary artery bypass grafts and recipient coronary arteries. Utility of fast cine magnetic reso nance imaging and display for the detection of myocardial ischemia in patients not well suited for second harmonic stress echocardiography. Diagnostic performance of stress cardiac magnetic resonance imaging in the detection of coronary artery disease. Prognostic value of cardiac magnetic resonance stress tests adenosine stress perfusion and dobutamine stress wall motion imaging. Fast 23Na magnetic resonance imaging of acute reperfused myocardial infarction potential to assess myocardial viability. Visualisation of pres ence, location, and transmural extent of healed Qwave and nonQwave myocar dial infarction. Diagnostic value of contrastenhanced mag netic resonance imaging and singlephoton emission computed tomography for detection of myocardial necrosis early after acute myocardial infarction. Characterization of the periinfarct zone by contrastenhanced cardiac magnetic resonance imaging is a powerful predictor of postmyocardial infarction mortality. Sequelae of acute myocardial infarction regarding cardiac structure and function and their prognostic significance as assessed by magnetic resonance imaging. Diagnostic performance of cardiovascular magnetic resonance in patients with suspected acute myocarditis: comparison of different approaches. Native T1mapping displays the extent and nonischemic patterns of injury in acute myocarditis without the need for contrast agents. Magnetic resonance assessment of the substrate for inducible ventricular tachycardia in nonischemic cardiomyopathy. Clinical characteristics and cardiovascular magnetic resonance findings in stress (takotsubo) cardiomyo pathy. Left ventricular noncompac tion: insights from cardiovascular magnetic resonance imaging. Diagnosis of arrhythmogenic right ven tricular cardiomyopathy/dysplasia proposed modification of the task force criteria. Noninvasive detection of myocardial fibrosis in arrhythmogenic right ventricular cardiomyopathy using delayed enhancement magnetic resonance imaging. Prognostic value of quantitative contrast enhanced cardiovascular magnetic resonance for the evaluation of sudden death risk in patients with hypertrophic cardiomyopathy. Comparison of surgical septal myec tomy and alcohol septal ablation with cardiac magnetic resonance imaging in patients with hypertrophic obstructive cardiomyopathy. Patterns of myocardial inflammation and scarring in sarcoidosis as assessed by cardiovas cular magnetic resonance. Assessment of lefttoright intracardiac shunting by velocityencoded, phasedifference magnetic resonance imaging a comparison with oximetric and indicator dilution techniques. Noninvasive quantification of lefttoright shunt in pediatric patients phasecontrast cine mag netic resonance imaging compared with invasive oximetry. Highresolution magnetic resonance angiography of the renal arteries using parallel imaging acquisition techniques at 3. Multimodality imaging in transcatheter aor tic valve implantation and postprocedural aortic regurgitation: comparison among cardiovascular magnetic resonance, cardiac computed tomography, and echocardiography.

In the left hand panel of this figure erectile dysfunction treatment devices purchase discount malegra fxt on line, similar treatment effects are obtained from two different studies erectile dysfunction 43 years old buy discount malegra fxt 140mg line, one of which is significant and one is not erectile dysfunction drugs causing order malegra fxt 140mg overnight delivery. The lack of significance alone should not be the sole metric on which to interpret the findings erectile dysfunction treatment viagra order malegra fxt in india, particularly as the effect size appears to be large erectile dysfunction medication australia cost of malegra fxt, albeit imprecise erectile dysfunction kya hota hai generic 140 mg malegra fxt with amex. Again, focusing on the pvalue alone as the sole discriminator of importance in treat ment effect would ignore the very large and perhaps clinically rele vant gradient of effect between the treatments. Quantitative data For a quantitative measure of patient outcome it is common to com pare the mean outcomes in each treatment group. If the data are normally dis tributed then appropriately 95% of individuals will have a value within two standard deviations either side of the mean. That is, precision in the estimated mean increases proportionately with the square root of the number of patients. Trial design: the fundamentals When planning a clinical trial much energy is devoted to defining exactly what is the new treatment, who are the eligible patients, and what are the primary and secondary outcomes. Such standard treatment can either be an established active treatment or no treat ment (possibly a placebo). Of course, all patients in both groups have good medical care in all other respects. Randomization One needs a fair (unbiased) comparison between new treatment and control, and randomization is the key requirement in this regard. That is, each patient has an equal chance of being randomly assigned to new or standard treatment. Furthermore, the method of handling random assignments is such that no one can predict in advance what each next patient will be assigned to . Thus, randomi zation ensures there is no selection bias in deciding which patients get new or standard treatment. Such selection bias is a serious problem in any observational (nonrandomized) studies compar ing treatments, making them notoriously unreliable in their conclusions. As a consequence, randomization minimizes the possibility that treatment groups will significantly differ in baseline characteristics. The possibility for chance variation can never be completely elimi nated, however, even in a randomized study design. To further guarantee that key baseline features will not influence the treatment effect, randomization can also be stratified, a common approach in multicenter studies. In addition, randomization helps to ensure that all other aspects of patient care, and also the evaluation of patient outcome, is identi cal in both treatment groups. In this respect it is often important to make the trial double blind whereby neither patients nor those treat ing them and evaluating their response know which treatment each individual patient is receiving. If a trial cannot be made double blind one can nevertheless require blinded evaluation of outcome by people not aware of which treatment each patient is on. Power calculations are the most commonly used statistical method for determining the required trial size. Large treatment effects, if present, can be detected in rela tively small trials so it is relevant to focus on what reasonably modest effect one would not wish to miss. Often, a single clinical trial is neither large nor representative enough to evaluate a particular therapeutic issue. Then, meta analyses can be of value in combining evidence from several related trial to reach an overall conclusion. From such information there are statistical formulae that provide the required number of patients. It is important to note that sample size is estimated in the design phase of a study using a priori assumptions that may or may not end up being correct. Poor design can result in an underpowered study that is unable to demonstrate reductions with a treatment effect that is in fact beneficial, thereby depriving patients of a therapeutic option. Alternatively, poor enrolment or event rate assumptions that are not realistic can result in significant expenditure of both human and financial resources in the execution of a study that is ultimately futile. Appreciating the nuances of sample size calcu lations is critical to the interpretation of clinical trial results, both positive and negative. The trial required 790 patients to yield 90% power to detect a 40% reduction in the primary endpoint. However, the trial was stopped early because of slow enrolment, after enrolling only 198 patients. Clearly there are many other important issues that need to be tackled in the design, conduct, analysis, and interpretation of clinical trials. All we can do here is briefly alert the reader to these topics and encourage them to pursue further from other courses, textbooks, publications, and so on. In trial design we have concentrated on parallel group trial with just two treatments. In this context the most common trial types include superiority and noninferiority designs. The key difference between these trial types relates to the expression of the null and alternative hypotheses for each respective design. In a classic superi ority trial the null hypothesis states that there are no differences between the experimental and control treatments whereas in a non inferiority trial the null hypothesis is formulated as the experimental treatment is worse than control by a prespecified margin. Similarly, the alternative hypothesis for a superiority trial assumes that the experimental and control treatments are different. The choice of superiority as compared to a noninferiority design is influenced by a number of factors including cost, existing therapies, and side effect profiles of different treatments. In addition, the great efficacy of certain treatments can require prohibitively large and expensive trials designed to show superiority. Such an anal ysis gives an unbiased comparison of the treatment policies as they were delivered in practice, a socalled pragmatic trial. Non-inferiority margin randomized treatment, are potentially biased as it could be the sicker patients who opt out. Reporting of trial findings in medical journals, at conference presentations, and to regulatory authorities need to be of the high est standards whereby an unbiased and detailed report of all rele vant findings is presented. The objectives, methods, discussion, and conclusions need to be clearly presented in a balanced report. In particular, results and interpretations should include any safety issues (adverse events) as well as efficacy findings. This article discusses the clinical data on sirolimus and paclitaxeleluting stents from pivotal trial to multi vessel disease treatment, focusing on their historical contribution to interventional cardiology. Paclitaxel is a natu ral diterpenoid extracted from the bark, roots, and leaves of several Taxus species, including Taxus brevifolia and Taxus media. Its effect has been mainly explained by its ability to stabilize microtu bules and thereby inhibit cell division in the G0/G1 and G2/M phases [16]. In fact, given the observed relative reductions in restenosisrelated endpoints with Interventional Cardiology: Principles and Practice, Second Edition. The trial confirmed safety and reported no stent thrombosis, no deaths, and a binary restenosis rate of 16% at 6 months. From 6 months to 3 years, there was only one cardiac death and no stent thrombosis. Its antiinflammatory and antiproliferative properties reduce smooth muscle cell proliferation in the arterial wall following stentinduced injury [28,29]. From this independent, patientlevel metaanalysis from the four principal Cypher trials it may be concluded that at 5year follow up of patients with single de novo native coronary lesions 2. American 669 844 374 1356 544 1452 119 314 1573 32 1259 151 1737 65 1835 129 1771 630 1119 770 1130 P = 0. Fiveyear composite event rates for death, myocardial infarction, or stroke are shown. Notwithstanding, all patients with complex multivessel coronary artery disease should be reviewed by both a cardiac surgeon and an interventional cardiologist to reach consensus on optimum treatment [55]. While a detailed summary of these data is beyond the scope of this review, a brief overview of the types of registry data currently available is instructive, and illustrates both the strengths and weaknesses of these types of analyses. While the sequential type of comparison attempts to limit selection bias (or decision making swaying the choice of one type of stent over the other), this analysis is subject to bias relating to differences in case selection, adjunctive pharmacology, and proce dural factors between two different time periods. Similarly, while the concurrent type of registry may be less subject to these latter biases, selection bias can have a major role in explaining differences between treatment groups. As a result, observational, nonrandomized com parisons between treatment groups are extremely valuable, but must be interpreted with caution despite efforts to statistically adjust for baseline differences between comparator groups. A clinical trial comparing three antithrombotic drug regimens after coronaryartery stenting. Restenosis detected by routine angiographic followup and late mortality after coronary stent placement. Balancing efficacy and safety of drugeluting stents in patients undergoing percutaneous coronary intervention. Comparison of a polymerbased paclitaxel eluting stent with a bare metal stent in patients with complex coronary artery dis ease: a randomized controlled trial. Paclitax eleluting versus uncoated stents in primary percutaneous coronary intervention. Safety of coronary sirolimuseluting stents in daily clinical practice: oneyear followup of the eCypher registry. The problem with composite end points in cardiovascular studies: the story of major adverse cardiac events and per cutaneous coronary intervention. Clinical outcomes and stent thrombosis following offlabel use of drugeluting stents. Paclitaxel inhibits arterial smooth muscle cell proliferation and migration in vitro and in vivo using local drug delivery. Neointimal thickening after stent delivery of paclitaxel: change in composition and arrest of growth over six months. Paclitaxel stent coating inhibits neointi mal hyperplasia at 4 weeks in a porcine model of coronary restenosis. Taxol inhibits neointimal smooth muscle cell accumulation after angioplasty in the rat. Randomized study to assess the effec tiveness of slowand moderaterelease polymerbased paclitaxeleluting stents for coronary artery lesions. Clinical efficacy of polymerbased paclitaxeleluting stents in the treatment of complex, long coronary artery lesions from a multicenter, randomized trial: support for the use of drug eluting stents in contemporary clinical practice. Lack of neointimal proliferation after implantation of sirolimuscoated stents in human coronary arteries: a quantitative coronary angiography and threedimensional intravascular ultrasound study. Sustained suppression of neointimal prolif eration by sirolimuseluting stents: oneyear angiographic and intravascular ultra sound followup. A randomized comparison of a sirolimus eluting stent with a standard stent for coronary revascularization. Fiveyear clinical outcomes after siroli museluting stent implantation: insights from a patientlevel pooled analysis of four randomized trials comparing sirolimuseluting stents with baremetal stents. Frequency and predictors of stent throm bosis after percutaneous coronary intervention in acute myocardial infarction. Randomized comparison of percutaneous coro nary intervention with coronary artery bypass grafting in diabetic patients. Fiveyear outcomes in patients with left main disease treated with either percutaneous coronary intervention or coronary artery bypass grafting in the synergy between percutaneous coronary intervention with taxus and cardiac surgery trial. A metaanalysis of 16 randomized trials of sirolimuseluting stents versus paclitaxeleluting stents in patients with coro nary artery disease. Unrestricted use of drugeluting stents compared with baremetal stents in routine clinical practice: findings from the National Heart, Lung, and Blood Institute Dynamic Registry. Stent thrombosis, myocardial infarction, and death after drugeluting and baremetal stent coronary interventions. Headtohead comparison of sirolimuseluting stents versus paclitaxeleluting stents in patients undergoing percutaneous coro nary intervention: a metaanalysis of 76 studies. Stent thrombosis late after implantation of first generation drugeluting stents: a cause for concern. Early and late coronary stent thrombosis of sirolimuseluting and paclitaxeleluting stents in routine clinical practice: data from a large twoinstitutional cohort study. Late clinical events after clopidogrel discontinuation may limit the benefit of drugeluting stents: an observational study of drugeluting versus baremetal stents. ChaptEr 32 CobaltChromium EverolimusEluting Stents Vikas Thondapu1, Yoshinobu Onuma2, Bimmer E. Despite their efficacy and resulting enthusiastic use, however, concerns rapidly surfaced over their longterm safety. The countless studies that emerged from this reassessment provided new insights into the complex relationship between stent and vessel wall, and a renewed focus on the stent platform, polymer, and drug. Factors such as strut thickness, polymer biocompatibility, and drug release kinetics are now known to influence vascular endothelial healing, a major factor in longterm stent outcomes. Cobaltchromium (CoCr) stents were largely born out of the need for a new generation of coronary stents preserving or improving the safety, efficacy, and deliverability of earlier iterations. The superior biomechanics and biocompatibility of these alloys serve as the platform for increasingly varied and innovative approaches to stent design. Finally, it should be understood that the chemical and material properties discussed are not meant to be exhaustive nor meant to suggest that CoCr alloys are the single best material for coronary stents; other excellent materials exist and more are in development. Rather, the goal is to illustrate that while CoCr alloys do have their limitations, they achieve a better balance than materials such as stainless steel.

Malegra fxt 140mg without a prescription. The Dove copyright 2009 Ed Braverman.